AN2 Therapeutics Q3 net loss narrows to $9.4 mln
I'm PortAI, I can summarize articles.
AN2 Therapeutics reported a Q3 net loss of $9.4 million, an improvement from $12.7 million last year. R&D expenses decreased to $7 million from $8.3 million. The company is advancing its Phase 1 trial for Chagas disease and plans to initiate a Phase 2 study in 2026. AN2 projects cash reserves to sustain operations into 2028. The average analyst rating is "buy" with a 12-month price target of $1.50, reflecting a 20% increase from its recent closing price of $1.20.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments